Table 3.
CD-associated characteristics of the 20 patients
| Clinical characteristic | Data |
|---|---|
| Montreal classification — no. (%) | |
| Age at CD diagnosis (A) | |
| A1 (Not more than 16 years) | 1 (5%) |
| A2 (More than17 years but no more than 40 years) | 15 (75%) |
| A3 (More than 40 years) | 4 (20%) |
| Location (L) | |
| L1 (Ileal) | 1 (5%) |
| L2 (Colonic) | 0 (0%) |
| L3 (Ileocolonic) | 19 (95%) |
| L4 (Upper gastrointestinal) | 11 (55%) |
| Behavior (B) | |
| B1 (Non-stricturing and non-penetrating) | 12 (60%) |
| B2 (Stricturing) | 0 (0%) |
| B3 (Penetrating) | 8 (40%) |
| P (Perianal disease) | 14 (70%) |
| Age at CD diagnosis — yr | 28.70±11.63 |
| Duration of CDa — mth | 84.00±77.81 |
| CDAIb | 244.05±130.76 |
| Active CDc — no. (%) | 13 (65%) |
| Erythrocyte sedimentation rate — mm per hr | 46.70±39.59 |
| C-reactive protein — mg per L | 18.85±24.41 |
| CD-related gastrointestinal surgery — no. (%) | 7 (35%) |
| CD treatment — no. (%) | |
| 5-aminosalicylic acid | 1 (5%) |
| Glucocorticoids | 2 (10%) |
| Biological agents | 9 (45%) |
| Immunosuppressive agents | 15 (75%) |
| Antibioticsd | 0 (0%) |
| Enteral nutrition | 4 (20%) |
a Duration of CD referred to the time interval from the first symptom of CD to data collection
b Crohn disease activity index (CDAI) was based on the CDAI calculation method of Best
c Active CD was defined as CDAI ≥ 150
d Antibiotics referred to the use of cephalosporin, sulfonamide, or anti-anaerobic bacteria drugs